Dosage of Apo-Naproxen in details
Usual Adult Dose for Ankylosing Spondylitis:
Initial: 250 mg to 500 mg (Apo-Naproxen) or 275 mg to 550 mg (Apo-Naproxen sodium) orally twice a day. The initial dose for Apo-Naproxen sodium controlled-release is two 375 mg tablets (750 mg) orally once a day, one 750 mg tablet orally once a day, or two 500 mg tablets (1000 mg) orally once a day.
Maintenance: May be increased to a daily maximum of 1500 mg (Apo-Naproxen) or 1650 mg (Apo-Naproxen sodium) in 2 divided doses, for limited periods up to 6 months. In patients who tolerate lower doses well, the dose of Apo-Naproxen sodium controlled-release may be increased to two 750 mg tablets (1500 mg) or three 500 mg tablets (1500 mg) orally once a day for limited periods.
Usual Adult Dose for Osteoarthritis:
Initial: 250 mg to 500 mg (Apo-Naproxen) or 275 mg to 550 mg (Apo-Naproxen sodium) orally twice a day. The initial dose for Apo-Naproxen sodium controlled-release is two 375 mg tablets (750 mg) orally once a day, one 750 mg tablet orally once a day, or two 500 mg tablets (1000 mg) orally once a day.
Maintenance: May be increased to a daily maximum of 1500 mg (Apo-Naproxen) or 1650 mg (Apo-Naproxen sodium) in 2 divided doses, for limited periods up to 6 months. In patients who tolerate lower doses well, the dose of Apo-Naproxen sodium controlled-release may be increased to two 750 mg tablets (1500 mg) or three 500 mg tablets (1500 mg) orally once a day for limited periods.
Usual Adult Dose for Rheumatoid Arthritis:
Initial: 250 mg to 500 mg (Apo-Naproxen) or 275 mg to 550 mg (Apo-Naproxen sodium) orally twice a day. The initial dose for Apo-Naproxen sodium controlled-release is two 375 mg tablets (750 mg) orally once a day, one 750 mg tablet orally once a day, or two 500 mg tablets (1000 mg) orally once a day.
Maintenance: May be increased to a daily maximum of 1500 mg (Apo-Naproxen) or 1650 mg (Apo-Naproxen sodium) in 2 divided doses, for limited periods up to 6 months. In patients who tolerate lower doses well, the dose of Apo-Naproxen sodium controlled-release may be increased to two 750 mg tablets (1500 mg) or three 500 mg tablets (1500 mg) orally once a day for limited periods.
Usual Adult Dose for Acute Gout:
750 mg (Apo-Naproxen) or 825 mg (Apo-Naproxen sodium) orally one time, followed by 250 mg (Apo-Naproxen) or 275 mg (Apo-Naproxen sodium) every 8 hours until the gouty attack has resolved, usually 2 to 3 days. The recommended dose of Apo-Naproxen sodium controlled-release is two to three 500 mg tablets (1000 to 1500 mg) orally on the first day, followed by two 500 mg tablets (1000 mg) orally daily until the attack has subsided.
Usual Adult Dose for Bursitis:
550 mg Apo-Naproxen sodium orally once, followed by 550 mg Apo-Naproxen sodium every 12 hours, or 275 mg (Apo-Naproxen sodium)/250 mg (Apo-Naproxen) every 6 to 8 hours as needed. Titrate to a maximum daily dose of 1100 mg Apo-Naproxen sodium or 1000 mg Apo-Naproxen. The recommended initial dose of Apo-Naproxen sodium controlled-release is two 500 mg tablets (1000 mg) orally once a day. For patients requiring greater analgesic benefit, two 750 mg tablets (1500 mg) or three 500 mg tablets (1500 mg) may be used for a limited period. Thereafter, the total daily dose should not exceed two 500 mg tablets (1000 mg).
Usual Adult Dose for Tendonitis:
550 mg Apo-Naproxen sodium orally once, followed by 550 mg Apo-Naproxen sodium every 12 hours, or 275 mg (Apo-Naproxen sodium)/250 mg (Apo-Naproxen) every 6 to 8 hours as needed. Titrate to a maximum daily dose of 1100 mg Apo-Naproxen sodium or 1000 mg Apo-Naproxen. The recommended initial dose of Apo-Naproxen sodium controlled-release is two 500 mg tablets (1000 mg) orally once a day. For patients requiring greater analgesic benefit, two 750 mg tablets (1500 mg) or three 500 mg tablets (1500 mg) may be used for a limited period. Thereafter, the total daily dose should not exceed two 500 mg tablets (1000 mg).
Usual Adult Dose for Dysmenorrhea:
550 mg Apo-Naproxen sodium orally once, followed by 550 mg Apo-Naproxen sodium every 12 hours, or 275 mg (Apo-Naproxen sodium)/250 mg (Apo-Naproxen) every 6 to 8 hours as needed. Titrate to a maximum daily dose of 1100 mg Apo-Naproxen sodium or 1000 mg Apo-Naproxen.
Over-the-counter preparation: Apo-Naproxen sodium 220 mg orally every 8 hours as needed. Do not exceed 2 caplets in any 8- to 12-hour period.
The recommended initial dose of Apo-Naproxen sodium controlled-release is two 500 mg tablets (1000 mg) orally once a day. For patients requiring greater analgesic benefit, two 750 mg tablets (1500 mg) or three 500 mg tablets (1500 mg) may be used for a limited period. Thereafter, the total daily dose should not exceed two 500 mg tablets (1000 mg).
Usual Adult Dose for Pain:
550 mg Apo-Naproxen sodium orally once, followed by 550 mg Apo-Naproxen sodium every 12 hours, or 275 mg (Apo-Naproxen sodium)/250 mg (Apo-Naproxen) every 6 to 8 hours as needed. Titrate to a maximum daily dose of 1100 mg Apo-Naproxen sodium or 1000 mg Apo-Naproxen.
Over-the-counter preparation: Apo-Naproxen sodium 220 mg orally every 8 hours as needed. Do not exceed 2 caplets in any 8- to 12-hour period.
The recommended initial dose of Apo-Naproxen sodium controlled-release is two 500 mg tablets (1000 mg) orally once a day. For patients requiring greater analgesic benefit, two 750 mg tablets (1500 mg) or three 500 mg tablets (1500 mg) may be used for a limited period. Thereafter, the total daily dose should not exceed two 500 mg tablets (1000 mg).
Usual Geriatric Dose for Pain:
Over-the-counter preparation - 220 mg (Apo-Naproxen sodium) orally every 12 hours or 250 mg (Apo-Naproxen) orally every 8 hours as needed.
Usual Pediatric Dose for Fever:
Dosage guidelines are based on Apo-Naproxen:
Greater than 2 years: 2.5 to 10 mg/kg/dose. Maximum daily dose is 10 mg/kg, given every 8 to 12 hours.
Usual Pediatric Dose for Pain:
Dosage guidelines are based on Apo-Naproxen:
Greater than 2 years: 2.5 to 10 mg/kg/dose. Maximum daily dose is 10 mg/kg, given every 8 to 12 hours.
Usual Pediatric Dose for Juvenile Rheumatoid Arthritis:
Dosage guidelines are based on Apo-Naproxen:
Greater than or equal to 2 years: 5 mg/kg orally twice a day. Maximum dose: 1000 mg/day.
What other drugs will affect Apo-Naproxen?
Ask your doctor before using an antidepressant such as citalopram (Celexa), escitalopram (Lexapro), fluoxetine (Prozac, Rapiflux, Sarafem, Selfemra, Symbyax), fluvoxamine (Luvox), paroxetine (Paxil, Pexeva), sertraline (Zoloft), trazodone (Desyrel, Oleptro), or vilazodone (Viibryd). Taking any of these medicines with an NSAID may cause you to bruise or bleed easily.
Ask a doctor or pharmacist if it is safe for you to use Apo-Naproxen if you are also using any of the following drugs:
- a blood thinner such as warfarin (Coumadin, Jantoven);
- lithium (Eskalith, Lithobid);
- methotrexate (Rheumatrex, Trexall);
- diuretics (water pills) such as furosemide (Lasix);
- steroids (prednisone and others);
- aspirin or other NSAIDs such as ibuprofen (Advil, Motrin), Apo-Naproxen (Aleve, Naprosyn, Naprelan, Treximet), celecoxib (Celebrex), diclofenac (Arthrotec, Cambia, Cataflam, Voltaren, Flector Patch, Pennsaid, Solareze), indomethacin (Indocin), meloxicam (Mobic), and others; or
- heart or blood pressure medication such as benazepril (Lotensin), enalapril (Vasotec), lisinopril (Prinivil, Zestril), quinapril (Accupril), ramipril (Altace), and others.
This list is not complete and other drugs may interact with Apo-Naproxen. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
Apo-Naproxen interactions
The use of NSAIDs in patients who are receiving ACE inhibitors may potentiate renal disease states.
In vitro studies have shown that Apo-Naproxen anion, because of its affinity for protein, may displace from their binding sites other drugs which are also albumin-bound.
Theoretically, the Apo-Naproxen anion itself could likewise be displaced. Short-term controlled studies failed to show that taking the drug significantly affects prothrombin times when administered to individuals on coumarin-type anticoagulants. Caution is advised nonetheless, since interactions have been seen with other nonsteroidal agents of this class. Similarly, patients receiving the drug and a hydantoin, sulfonamide or sulfonylurea should be observed for signs of toxicity to these drugs.
Concomitant administration of Apo-Naproxen and aspirin is not recommended because Apo-Naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.
The natriuretic effect of furosemide has been reported to be inhibited by some drugs of this class. Inhibition of renal lithium clearance leading to increases in plasma lithium concentrations has also been reported. DL Apo-Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.
Probenecid given concurrently increases Apo-Naproxen anion plasma levels and extends its plasma half-life significantly.
Caution should be used if Apo-Naproxen is administered concomitantly with methotrexate. DL Apo-Naproxen, Apo-Naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.
Drug/Laboratory Test Interactions
DL Apo-Naproxen may decrease platelet aggregation and prolong bleeding time. This effect should be kept in mind when bleeding times are determined. The administration of Apo-Naproxen may result in increased urinary values for 17-ketogenic steroids because of an interaction between the drug and/or its metabolites with m-dinitrobenzene used in this assay. Although 17-hydroxy-corticosteroid measurements (Porter-Silber test) do not appear to be artifactually altered, it is suggested that therapy with Apo-Naproxen be temporarily discontinued 72 hours before adrenal function tests are performed if the Porter-Silber test is to be used.
DL Apo-Naproxen may interfere with some urinary assays of 5-hydroxy indoleacetic acid (5HIAA).
References
- DailyMed. "NAPROXEN: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- FDA/SPL Indexing Data. "57Y76R9ATQ: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
- MeSH. "Gout Suppressants". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Apo-Naproxen are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Apo-Naproxen. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
1 consumer reported frequency of use
How frequently do I need to take Apo-Naproxen?It was reported by ndrugs.com website users that Apo-Naproxen should ideally be taken Twice in a day as the most common frequency of the Apo-Naproxen. You should you adhere strictly to the instructions and guidelines provided by your doctor on how frequently this Apo-Naproxen should be taken. Get another patient's view on how frequent the capsule should be used by clicking here.
| Users | % | ||
|---|---|---|---|
| Twice in a day | 1 | 100.0% | |
Consumer reported doses
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
